Physician profile
David A Dalessandro
NPI 1538200720
$13,128.55
in general payments reported to CMS, 2019-2025
39 companies · $2,420 in 2025
The $2,420 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,682 · 2020: $1,327 · 2021: $2,172 · 2022: $1,568 · 2023: $1,906 · 2024: $2,054 · 2025: $2,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,316 · Education: $63.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,316.17 |
| Education | $63.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,895.69 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,753.80 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,113.87 | 2019-2025 | Lifevest |
| Amgen INC. | $1,077.65 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $902.94 | 2019-2025 | Farxiga, Brilinta |
| Pfizer INC. | $875.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $784.53 | 2019-2025 | Jardiance |
| Abiomed | $512.98 | 2021-2025 | Impella |
| Merck Sharp & Dohme LLC | $512.97 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $486.28 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $467.87 | 2021-2025 | Nexletol |
| Boston Scientific Corporation | $396.64 | 2019-2025 | Watchman Flx |
| Novo Nordisk INC | $289.09 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $241.75 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $198.89 | 2022-2025 | Opsumit, Uptravi |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $171.23 | 2025 | Symplicity G3 |
| Daiichi Sankyo INC. | $165.90 | 2019-2024 | Injectafer |
| Atricure, INC. | $152.90 | 2023 | |
| Amarin Pharma, INC. | $149.67 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $144.70 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $109.99 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $100.77 | 2025 | |
| Vifor Pharma, INC. | $80.88 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $67.41 | 2019-2021 | |
| Tactile Systems Technology INC | $64.29 | 2025 | Flexitouch Plus, Nimbl |
| Abbott Laboratories | $58.16 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Impulse Dynamics (USA) INC. | $49.69 | 2024 | Optimizer |
| Alnylam Pharmaceuticals INC. | $49.06 | 2024-2025 | Onpattro |
| Philips North America LLC | $35.19 | 2024 | (Ck7) Extended Holter |
| Altathera Pharmaceuticals LLC | $29.77 | 2023-2024 | Sotalol Hydrochloride |
| Davol INC. | $29.66 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $27.76 | 2021-2023 | Arcalyst |
| Heartflow, INC. | $27.18 | 2024 | |
| Mannkind Corporation | $26.81 | 2025 | |
| Bardy Diagnostics, INC. | $20.00 | 2020 | |
| Braemar Manufacturing, LLC | $17.61 | 2019 | |
| Teleflex LLC | $15.06 | 2022 | |
| Biotronik INC. | $13.74 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dalessandro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.